Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

EVA: Evista Alendronate Comparison

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00035971
Recruitment Status : Completed
First Posted : May 8, 2002
Last Update Posted : July 19, 2006
Information provided by:
Eli Lilly and Company

Brief Summary:
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures

Condition or disease Intervention/treatment Phase
Osteoporosis Drug: raloxifene HCI and alendronate Na Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • 50-80 years of age, inclusive
  • 2 years since last menses
  • Dx femoral neck osteoporosis
  • No vertebral fractures

Exclusion Criteria

  • Poor candidate for study drugs
  • Hx of diseases affecting bone metabolism
  • Hx of breast/estrogen-dependent cancer
  • Current use of osteoporosis drug therapy
  • Hx/high risk of VTE

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00035971

Show Show 86 study locations
Sponsors and Collaborators
Eli Lilly and Company

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00035971    
Other Study ID Numbers: 5548
First Posted: May 8, 2002    Key Record Dates
Last Update Posted: July 19, 2006
Last Verified: July 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Raloxifene Hydrochloride
Bone Density Conservation Agents
Physiological Effects of Drugs
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators